Outlook
- Steris reiterates fiscal 2027 revenue growth guidance of 7-8% as reported
- Company expects fiscal 2027 adjusted EPS of $11.10 to $11.30
- Steris raises fiscal 2027 capital expenditures outlook to $450 mln, lowers free cash flow view to $800 mln
Overview
- Ireland-based infection prevention firm's fiscal Q1 revenue rose 7% yr/yr
- Adjusted EPS for fiscal Q1 beat analyst expectations
- Company announced a restructuring plan tied to a new chemistries Center of Excellence in North Carolina
Result drivers
- Healthcare segment growth - The company said Healthcare segment growth was driven by share gains in consumables and services, with solid order growth for capital equipment
- Price and volume improvements - The company attributed higher operating income in Healthcare and Life Sciences to improved volume, price, productivity and favorable mix, partially offset by inflation and tariff costs
- AST segment mixed results - The company said Applied Sterilization Technologies revenue rose on service growth but was held back by a decline in capital equipment sales
Key details and analyst coverage
STE•
